{
    "clinical_study": {
        "@rank": "80786", 
        "arm_group": [
            {
                "arm_group_label": "MT-2301-Low", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MT-2301-High", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ActHib", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered\n      with DPT-IPV using ActHIB\u00ae as a control in healthy infants."
        }, 
        "brief_title": "Exploratory Clinical Study of MT-2301", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Haemophilus Influenza Type b", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy infants aged \u22652 and <7 months at the first vaccination of the study drug\n\n          -  Written informed consent is obtained from a legal guardian (parent)\n\n        Exclusion Criteria:\n\n          -  With obvious pyrexia (axillary temperature of 37.5\u00baC or higher) at vaccination of the\n             study drug\n\n          -  With known serious acute disease\n\n          -  With known underlying disease such as cardiovascular disease, renal disease, hepatic\n             disease, blood dyscrasia, and respiratory disease\n\n          -  With past diagnosis of immunodeficiency or currently under immunosuppressive\n             treatment\n\n          -  History of anaphylaxis due to food or pharmaceuticals\n\n          -  With experience of Hib infection, diphtheria, pertussis, tetanus, and acute\n             poliomyelitis\n\n          -  With experience of  Hib vaccination, or administration of vaccine including either\n             diphtheria, pertussis, tetanus, or polio as a constituent\n\n          -  History of convulsions\n\n          -  Administered a live vaccine within 27 days before the first vaccination of the study\n             drug, or inactivated vaccine or toxoid within 6 days before vaccination\n\n          -  Administered transfusion, immunosuppressant (excluding drugs for external use), or\n             immunoglobulin formulation\n\n          -  Administered corticosteroid 2 mg/kg per day or more as prednisolone (excluding drugs\n             for external use) continuously for more than 1 week\n\n          -  Participated in other studies within 12 weeks before obtaining consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "7 Months", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140047", 
            "org_study_id": "MT-2301-J01"
        }, 
        "intervention": [
            {
                "arm_group_label": "MT-2301-Low", 
                "description": "0.25mL, subcutaneous injection", 
                "intervention_name": "Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV", 
                "intervention_type": "Biological", 
                "other_name": "MT-2301-Low + Tetrabik\u00ae"
            }, 
            {
                "arm_group_label": "MT-2301-High", 
                "description": "0.5mL, subcutaneous injection", 
                "intervention_name": "Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV", 
                "intervention_type": "Biological", 
                "other_name": "MT-2301-High + Tetrabik\u00ae"
            }, 
            {
                "arm_group_label": "ActHib", 
                "description": "0.5mL, subcutaneous injection", 
                "intervention_name": "Haemophilus influenza type b conjugate vaccine + DPT-IPV", 
                "intervention_type": "Biological", 
                "other_name": "ActHib\u00ae + Tetrabik\u00ae"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Haemophilus influenza type b", 
            "Hib"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fukuoka-shi", 
                    "country": "Japan", 
                    "state": "Fukuoka"
                }, 
                "name": "Investigational site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Exploratory Clinical Study of MT-2301 in Healthy Infants (Phase 2)", 
        "overall_contact": {
            "email": "cti-inq-ml@ml.mt-pharma.co.jp", 
            "last_name": "Clinical Trials Information Desk"
        }, 
        "overall_official": {
            "affiliation": "Department of pediatrics, Kawasaki Hospital, Kawasaki Medhical School", 
            "last_name": "Takashi Nakano, M.D., Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Anti-PRP antibody prevalence rate with 1 \u03bcg/mL or higher", 
            "safety_issue": "No", 
            "time_frame": "4 weeks after the primary immunization (Visit 4)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140047"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Anti-PRP antibody prevalence rate with 0.15 \u03bcg/mL or higher", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after the primary immunization (Visit 4)"
            }, 
            {
                "measure": "Geometric mean antibody titer (GMT) of anti-PRP antibody", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after the primary immunization (Visit 4)"
            }, 
            {
                "measure": "Anti-PRP antibody prevalence rate with 1 \u03bcg/mL or higher", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after the booster dose (Visit 6)"
            }, 
            {
                "measure": "Anti-PRP antibody prevalence rate with 0.15 \u03bcg/mL or higher", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after the booster dose (Visit 6)"
            }, 
            {
                "measure": "Geometric mean antibody titer (GMT) of anti-PRP antibody", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after the booster dose (Visit 6)"
            }, 
            {
                "measure": "Antibody prevalence rate and geometric mean antibody titer (GMT) against diphtheria toxin, pertussis, tetanus toxin, and less virulent strain of polio virus", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after the primary immunization (Visit 4)"
            }, 
            {
                "measure": "Antibody prevalence rate and geometric mean antibody titer (GMT) against diphtheria toxin, pertussis, tetanus toxin, and less virulent strain of polio virus", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after the booster dose (Visit 6)"
            }, 
            {
                "measure": "Adverse events and adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "through the first dose (Visit 1) to 4 weeks after the booster dose (Visit 6)"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}